GLP-1 Agonists for Diabetes: Mounjaro Versus Ozempic
XTalks
NOVEMBER 9, 2022
Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. dependent insulin secretion and suppression of glucagon release. And the demand won’t be easing anytime soon. mediated glucose?dependent
Let's personalize your content